Trademark Overview
On Wednesday, June 4, 2025, a trademark application was filed for BLUEFIN BIOMEDICINE with the United States Patent and Trademark Office. The USPTO has given the BLUEFIN BIOMEDICINE trademark a serial number of 99218533. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Wednesday, June 4, 2025. This trademark is owned by Bluefin Biomedicine, Inc.. The BLUEFIN BIOMEDICINE trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Antibodies for medical purposes; Diagnostic biomarker reagents for medical purposes; Protein arrays for medical diagnosis purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic preparations for medical purposes; Pharmaceutical preparations for the treatment of cancer, oncologic diseases and disorders, inflammation and immunity diseases and disorders, immunodeficiency diseases and disorders, genetic diseases and disorders, metabolic diseases and disorders, neurodegenerative diseases and disorders, kidney diseases and disorders, eye diseases and disorders, uveitis, glomerulosclerosis, glomerulonephritis, cardiovascular diseases and disorders
Pharmaceutical research and development; Research and development services in the field of antibodies; Providing medical and scientific research information; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of biotechnology; Consulting services in the field of pharmacogenetics; Research and development in the field of biologics, namely, antibodies and peptides for the field of cancer, immunology and inflammation diseases, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, uveitis, glomerulosclerosis, glomerulonephritis, and cardiovascular diseases; Research and development in the field of pharmaceuticals, biopharmaceuticals, and biotechnologies for the treatment of cancer, immunology and inflammation diseases, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, ey...
